Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data SI-BONE, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
48
55.4
67.3
73.4
90.2
106
139
167
201
Cost of revenue
5.11
4.83
6.79
8.9
10.4
15.7
29.5
35.1
41
Gross profit
42.9
50.5
60.5
64.5
79.7
90.7
109
132
160
Research and development
5.51
5.38
7.28
9.46
12.4
13.6
15
16.6
17.4
Selling and marketing
41.6
44.5
68.3
73.8
93.9
108
110
117
124
General and administrative
13.1
12.6
21
19.8
25.1
29
31.1
33.8
40.5
Operating expenses
60.2
62.5
96.5
103
131
150
156
167
182
Operating income
-17.4
-12
-36
-38.6
-51.7
-59.6
-46.9
-35.2
-22.3
Interest expense
6.2
5.11
4.95
6.1
5.37
2.82
3.46
3.44
2.63
Interest income
0.18
0.77
2.55
1.1
0.19
1.3
6.92
7.85
6.07
Other non-operating income
0.34
-1.15
-0
-0.13
0.28
-0.13
0.14
-0.07
-0.02
Pre-tax income
-23
-17.5
-38.4
-43.7
-57
-61.4
-43.5
-31.1
-19.1
Income tax
0
0
0
0
0
0
0
Net income
-23
-17.5
-38.4
-43.7
-56.6
-61.3
-43.3
-30.9
-18.9
EBITDA
-16.3
-11.2
-35.2
-37.4
-49.6
-56.2
-41.5
-30.9
-16.6
EPS, basic
-6.65
-2.20
-1.55
-1.50
-1.71
-1.79
-1.13
-0.75
-0.44
EPS, diluted
-6.65
-2.20
-1.55
-1.50
-1.71
-1.79
-1.13
-0.75
-0.44
Shares, basic (weighted)
3.47
7.95
24.7
29.1
33.1
34.2
38.4
41.5
43
Shares, diluted (weighted)
3.47
7.95
24.7
29.1
33.1
34.2
38.4
41.5
43
Dividend per share
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22.4
25.1
10.4
53.6
63.4
20.7
33.3
34.9
42.2
Short-term investments
97.1
81.3
143
83.6
76.6
Receivables
7.42
8.49
11.7
13.6
14.2
20.7
22
27.5
29.9
Inventory
2.55
3.34
5.45
5.63
11.5
17.3
20.2
27.1
33.9
Other current assets
1.25
1.99
2.51
2.57
3.14
2.37
3.17
3.2
4.48
Total current assets
33.6
136
111
218
176
138
211
208
216
Property, plant and equipment
1.9
2.15
3.95
4.53
8.99
15.6
16
20.4
21.3
Lease right-of-use assets
0
5.25
4
2.71
1.98
1.09
Long-term investments
0
1.28
0
Other non-current assets
0.31
0.33
0.32
0.37
0.4
0.38
0.33
0.3
0.06
Total assets
35.8
139
117
223
191
158
230
230
239
Accounts payable
1.81
2.15
2.81
3.27
3.2
6.28
4.59
6.49
4.63
Accrued liabilities
5.72
6.86
11.6
10.2
12.4
13.5
17.5
19.5
19.7
Short-term debt
0
4.36
0
0
Total current liabilities
7.54
9.01
18.8
13.5
16.9
21.2
23.5
27.1
25.3
Long-term debt
38.7
39
34.9
39.5
35
35.2
36.1
35.5
35.6
Lease liabilities
0
4.17
2.87
1.51
0.88
0.18
Other non-current liabilities
0
0.36
0.36
0.85
0.06
0.03
0.02
0.01
0
Total liabilities
46.7
48.3
54
53.8
56.1
59.3
61.1
63.5
61
Total debt
38.7
39
39.2
39.5
35
35.2
36.1
35.5
35.6
Paid-in capital
9.94
247
258
408
430
455
569
598
627
Retained earnings
-140
-157
-196
-239
-296
-357
-400
-431
-450
Other comprehensive income
0.4
0.44
0.46
0.52
0.35
0.23
0.34
0.24
0.82
Shareholders' equity
-129
90.2
63
169
134
98.3
169
167
178
Total equity
-129
90.2
63
169
134
98.3
169
167
178
Total liabilities and equity
35.8
139
117
223
191
158
230
230
239
Shares outstanding
3.6
24.5
25.2
32.6
33.7
34.7
40.7
42.1
43.6
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-23
-17.5
-38.4
-43.7
-56.6
-61.3
-43.3
-30.9
-18.9
Depreciation and amortization
1.01
0.72
0.77
1.13
2.09
3.45
5.43
4.38
5.77
Stock-based compensation
1.44
2.31
7.46
11.9
16.9
23.1
24.1
25.9
25.5
Deferred income tax
-7.51
4.58
9.89
13.1
15.3
16
12.4
-6.01
2.07
Change in receivables
-1.31
-1.03
-3.24
-2.19
-0.57
-6.48
-2.12
-5.84
-3.03
Change in inventory
-0.98
-0.76
-2.11
-0.27
-5.78
-6.03
-4.72
-8.05
-8.68
Change in payables
0.81
0.25
0.38
0.84
-0.53
2.53
-1.12
1.86
-1.76
Cash from operations
-17.5
-14.5
-31.6
-30.7
-39.5
-41.7
-18.7
-12.4
-0.68
Capital expenditures
-0.48
-0.94
-2.45
-2.56
-6.39
-9.51
-7.8
-10.5
-8.41
Purchases of investments
0
-96.9
-144
-179
-102
-120
-189
-205
-193
Sales and maturities of investments
0
160
Cash from investing
-0.48
-97.8
13.5
-62.9
51.6
-2.82
-59.8
12.6
4.16
Debt issued
40
0
0
45.3
35
0
36
36
0
Debt repaid
-1.12
0
0
-45.3
-41
0
-35.3
-36
0
Stock issued
0.38
1.61
0
135
0
0
83.7
0
0
Share buybacks
0
-0.07
-0.04
Cash from financing
12.9
115
3.49
136
-1.71
2.2
90.9
1.96
3.38
Exchange rate effect
-0.35
-0.09
-0.04
0.32
-0.5
-0.43
0.13
-0.48
0.43
Net change in cash
-5.49
2.71
-14.7
43.1
9.84
-42.7
12.6
1.68
7.29
Free cash flow
-18
-15.5
-34.1
-33.2
-45.9
-51.2
-26.5
-22.9
-9.09
Interest paid
4.51
5.5
4.95
4.28
3.23
2.62
3.26
3.35
2.53
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $18.59 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
79.5%
Gross profit / revenue.
Operating margin
-8.3%
Operating income / revenue.
EBITDA margin
-5.3%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-6.9%
Net income / revenue.
FCF margin
-2.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
1.2%
Cash from operations / revenue.
Return on equity (ROE)
-8.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-5.9%
Net income / average total assets.
Return on invested capital (ROIC)
-7.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
8.4%
Research and development expense / revenue.
Stock-based pay / revenue
11.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
3.2%
Capital expenditures / revenue.
D&A / revenue
3.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
20.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
23.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
22.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
21.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
20.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
19.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
6.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
21.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
0.9%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
3.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
14.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
1.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
7.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
8.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.15x
Current assets / current liabilities.
Quick ratio
2.67x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.38x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.20x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
14.3%
Total debt / total assets.
Liabilities / assets
26.7%
Total liabilities / total assets.
Net debt
$2.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Capex / operating cash flow
277.0%
Capital expenditures / cash from operations, when that is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.33
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$4.80
Revenue / diluted weighted shares.
FCF per share
-$0.10
Free cash flow / diluted weighted shares.
Operating cash flow per share
$0.06
Cash from operations / diluted weighted shares.
Book value per share
$4.08
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
3.90x
Market cap / revenue.
P/B
4.57x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
4.57x
Market cap / tangible book value, when positive.
P/OCF
336x
Market cap / cash from operations, when positive.
EV/Sales
3.91x
Enterprise value / revenue.
FCF yield
-0.5%
Free cash flow / market cap.
Earnings yield
-1.8%
Net income / market cap (the inverse of P/E).
What was SI-BONE, Inc.'s revenue in fiscal 2025?
SI-BONE, Inc. reported revenue of $200.9M for fiscal 2025, 20.2% higher than the year before.
Was SI-BONE, Inc. profitable in fiscal 2025?
No. It reported a net loss of $18.9M.
How much free cash flow did SI-BONE, Inc. generate in fiscal 2025?
Cash from operations of $675.0K minus capital expenditures of $8.4M left free cash flow of -$9.1M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.